In a screen of 537 human tumor cell lines, 87 (16%) had GI25 values below 1 μM G007-LK. Follow-up MTS assays gave GI50 values of 54–844 nM in four selected sensitive lines, while RKO had a GI50 above 1000 nM. Potencies differed between the initial screen and validation assays, supporting an assay- and model-specific interpretation. [1]
In SW480 cells, 50 nM G007-LK overnight reduced β-catenin-dependent reporter activity by about 40%. Combining it with expression of an AXIN2-derived P182–195 peptide increased the reported inhibition to about 75%; peptide expression alone also inhibited the reporter. This reporter experiment supports a combination effect, without establishing formal pharmacological synergy or a G007-LK growth effect. [2]
Tumor-cell screening and selected-cell validation
Cell-based study · 537 human tumor cell lines from 29 tissue origins; follow-up COLO 320DM, UO-31, OVCAR-4, ABC-1 and negative-control RKO [1]
A minority of screened lines met the GI25 threshold. Selected sensitive lines were validated by MTS assays, with RKO serving as an insensitive comparator. Initial screen and follow-up GI50 values differ and should remain assay-specific.
Literature-Reported Treatment Conditions
- Treatment concentration
- Various concentrations; GI25 threshold <1 μM; selected-cell MTS dose responses shown in Fig. 1C.
- Exposure duration
- Initial NCI-60 panel: 48 h; Genentech panel: 72 h. MTS validation: Fig. 1C states 4–8 days; shared Proliferation assays methods state 5–8 days.
- Method
- Initial screening: SRB (NCI-60) or CellTiter-Glo (Genentech); follow-up endpoint MTS absorbance at 492 nm, normalized to vehicle and time-zero values.
- Vehicle
- DMSO controls in initial screens; follow-up MTS: 0.01% DMSO.
- Reported limits
- Exact validation duration for each cell line is not specified in Fig. 1; figure and shared methods give overlapping but different ranges. These values are growth-inhibition endpoints, not biochemical IC50 values.
Methods and source locations
Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK
Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.
Results, proliferation screen first two paragraphs; Fig. 1A–D; key resources and selected screening/treatment/MTS methods
Lines with GI25 <1 μM G007-LK: Two initial screening panels with different readouts and durations; author-reported aggregate. — Results, proliferation screen first paragraph; Fig. 1A; STAR Methods, Human tumor cell line anti-proliferative screens
Selected-cell MTS growth inhibition: Endpoint MTS; Fig. 1C: mean ± SD for one representative experiment of at least two repeated assays, each with six replicates. Values transcribed from the viewed Fig. 1D table, not estimated from bars. — Fig. 1C–D and caption; STAR Methods, Proliferation assays
AXIN stabilization and model-dependent Wnt reporter response
Cell-based study · COLO 320DM, UO-31, OVCAR-4, ABC-1 and RKO tumor cell lines [1]
G007-LK stabilized AXIN1 across this panel, while AXIN2 stabilization and β-catenin changes depended on cell type. Detectable dose-dependent reporter inhibition within the tested range was confined to COLO 320DM. This does not explain all growth responses in the selected cell lines.
Literature-Reported Treatment Conditions
- Treatment concentration
- Immunoblots: 1 μM. Reporter: concentration-response assay; values in Fig. 3F.
- Exposure duration
- Immunoblots: 24 or 72 h; stable Wnt reporter concentration-response: 72 h.
- Method
- Cytoplasmic/nuclear immunoblots with actin and lamin B1 loading controls; Wnt-responsive luciferase normalized to Renilla. Baseline TOP/FOP controls shown separately in Fig. 3E.
- Vehicle
- 0.01% DMSO
- Reported limits
- Biochemical target IC50, direct binding and a universal cellular potency are not measured by these readouts.
Methods and source locations
Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK
Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.
Results, WNT/β-catenin subsection; Fig. 3D–F; key resources, treatment, immunoblot and reporter readout methods
AXIN and β-catenin protein responses: Representative blots from two or more independent experiments; actin and lamin B1 loading controls. No numerical fold change inferred. — Fig. 3D and caption; Results, G007-LK inhibits WNT/β-catenin signaling
Wnt/β-catenin luciferase reporter suppression: 72-h reporter assay relative to 0.01% DMSO; table values transcribed from viewed Fig. 3F. These are reporter endpoints, not growth GI50 or enzyme IC50. — Fig. 3E–F and caption; STAR Methods, Luciferase reporter assays (readout/normalization)
G007-LK and an AXIN2-derived peptide in a factorial reporter assay
Cell-based study · SW480 colorectal cancer cells transfected with a peptide-expression construct [2]
G007-LK alone and low-dose expression of the AXIN2-derived P182–195 peptide each reduced β-catenin-dependent reporter activity. Their combination produced a larger reduction in the same experiment. The peptide is an expressed construct here, not the separately tested synthetic cell-penetrating peptide.
Literature-Reported Treatment Conditions
- Treatment concentration
- G007-LK: 50 nM; peptide-expression vector: 5 ng per 12-well transfection.
- Exposure duration
- G007-LK overnight (Fig. 7m).
- Method
- TOP/FOP luciferase reporter with β-galactosidase normalization; untreated/no-peptide, peptide-only, G007-LK-only and combination conditions.
- Co-treatment
- G007-LK plus expressed P182–195 peptide; single-agent comparators included.
- Reported limits
- Drug vehicle not specified in the selected methods/caption. Overnight is the reported duration; no exact hour count inferred.
Methods and source locations
Compound reported in the paper: G007-LK; Compound label in the paper: G007-LK
Applies to the paper’s named G007-LK preparation and stated model/assay; does not validate a present supplier lot or another form.
Results, final paragraph before Discussion; Fig. 7a,m; Methods, Cell culture/transfection/small chemicals and Luciferase reporter assay
β-catenin-dependent transcription: Author-text approximations, consistent with viewed Fig. 7m. Caption reports mean ± SEM (n=3); shared reporter methods specify technical duplicates. No formal synergy model or proliferation endpoint claimed. — Results, final paragraph before Discussion; Fig. 7a,m and caption; Methods, Luciferase reporter assay